ArticleIn vivo (Athens, Greece)
Elevated Serum Interleukin 6 Is Associated With High Risk of First Non-bleeding Decompensation in Patients With Compensated Cirrhosis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe transition from compensated to decompensated cirrhosis indicates a poor prognosis, and decompensated symptoms are subclassified as bleeding and non-bleeding. This study aimed to investigate the association between serum systemic inflammation marker levels and the development of the first bleeding and non-bleeding decompensation in patients with compensated cirrhosis. PATIENTS AND
methodsThis retrospective study included 214 patients with compensated liver cirrhosis. The baseline serum C-reactive protein, interleukin 6, procalcitonin, and serum amyloid A protein levels were measured. Factors associated with the first decompensation were assessed using the Cox proportional hazards model. The probability of first decompensation was evaluated using Kaplan-Meier analysis and the log-rank test.
resultsIn the study cohort, 167 (78%) patients showed elevation of one or more systemic inflammation markers. During a median follow-up of 3.6 years, 28 and 35 patients developed first bleeding and non-bleeding decompensation, respectively. The multivariate Cox proportional hazards model identified that nonviral etiology and low platelet count were significantly associated with bleeding decompensation and nonviral etiology, albumin-bilirubin grade, and serum interleukin 6 level with non-bleeding decompensation. Kaplan-Meier analyses showed that patients with high serum interleukin 6 levels (≥10 pg/ml) showed significantly higher probability of first non-bleeding decompensation than those with low serum interleukin 6 levels, but probability of bleeding decompensation was not different between them.
conclusionSerum pro-inflammatory cytokine interleukin 6 predicts the risk of first non-bleeding decompensation but not bleeding decompensation in patients with compensated cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.